BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,549,674 | -44.5% | 134,989 | -39.1% | 0.06% | -49.6% |
| Q3 2022 | $2,793,000 | +19.1% | 221,699 | 0.0% | 0.12% | +31.5% |
| Q2 2022 | $2,346,000 | -34.9% | 221,699 | 0.0% | 0.09% | -19.8% |
| Q1 2022 | $3,605,000 | +17.4% | 221,699 | 0.0% | 0.11% | +30.6% |
| Q4 2021 | $3,071,000 | +64.8% | 221,699 | +70.9% | 0.08% | +63.5% |
| Q3 2021 | $1,864,000 | -30.1% | 129,688 | -23.1% | 0.05% | -16.1% |
| Q2 2021 | $2,667,000 | +55.4% | 168,715 | 0.0% | 0.06% | +63.2% |
| Q1 2021 | $1,716,000 | -49.7% | 168,715 | -63.2% | 0.04% | -51.3% |
| Q4 2020 | $3,413,000 | +114.9% | 458,075 | -0.9% | 0.08% | +100.0% |
| Q3 2020 | $1,588,000 | -27.9% | 462,402 | 0.0% | 0.04% | -22.0% |
| Q2 2020 | $2,203,000 | +42.8% | 462,402 | -40.1% | 0.05% | +28.2% |
| Q1 2020 | $1,543,000 | – | 771,386 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $50,998,000 | 20.86% |
| RTW INVESTMENTS, LP | 3,458,120 | $29,048,000 | 7.65% |
| ISZO CAPITAL MANAGEMENT LP | 307,366 | $2,582,000 | 4.49% |
| DAFNA Capital Management LLC | 541,128 | $4,545,000 | 3.84% |
| RA Capital Management | 3,489,795 | $29,314,000 | 3.60% |
| EMORY UNIVERSITY | 375,348 | $3,153,000 | 2.98% |
| Ghost Tree Capital, LLC | 1,500,000 | $12,600,000 | 2.35% |
| ACUTA CAPITAL PARTNERS, LLC | 920,310 | $7,731,000 | 1.83% |
| Avoro Capital Advisors LLC | 1,603,001 | $13,465,000 | 1.72% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,085,236 | $25,916,000 | 1.00% |